Abstract:Aim: To observe the effect of long-time intake of phecyclidine (PCP), the receptor antagonist of noncompetitive N-methyl-D-aspartic acid (NMDA), on the social behavior of mice, and establish animal models of schizophrenia as well as observe the interventional effects of different antipsychotics on mouse models. Methods: The experiment was conducted in the Animal Laboratory of Medical Department, Nagoya University of Japan between June and September 2003. 1 First experiment, the effects of PCP on social behavior of mice at different dose and administration time: 60 DDY male mice of 6 months old were randomly divided into 5 groups after 2-week feeding with 12 mice in each group and fed in two separate coops. Mice in high-dose long-term PCP group were treated with 10 mg/kg for 14 days. Mice in low-dose long-term PCP group were treated with 3 mg/kg for 14 days, and mice in long-term administration control group were treated with normal saline for 14 days. Mice in high-dose short-term PCP group were treated with 3 mg/kg for 14 days. Mice in long-term administration control group were treated with normal saline for 14 days. Mice in high-dose short-term PCP group were treated with 10 mg/kg for 7 days. Mice in short-term administration control group were treated with normal saline for 7 days. All mice were administrated by subcutaneous injection. The social behaviors of mice were tested respectively on the 36rd, 7th, 14th, 21st and 28th day after drug withdrawal. 2 Second experiment. The effects of antipsychotics PCP on the social behaviors of mice: another 60 mice were randomly divided into 5 groups with 12 rats in each group, which were fed in two separate coops. Mice in high-dose clozapine group were continuously injected with high-dose PCP for 14 days, and then were injected with clozapine 3 mg/kg per day for 7 days at 14 days after withdrawal. Mice in high-dose aloperidin group were continuously injected with high dose of PCP for 14 days and then were injected with aloperidin 3 mg/kg per day for 7 days at 14 days after withdrawal. Mice in low-dose aloperidin group were continuously injected with high-dose alperidin for 14 days, and then were injected with alperidin 1 mg/kg per day for 7 days. Mice in the normal saline group were continuously injected with normal saline for 14 days and then were injected with normal saline for 7 days at 14 days after withdrawal. Social behaviors were tested on withdrawal day and 7 days after withdrawal. Results: All of 120 mice were involved in the analysis of results, and no one withdrew from the study. 1 The first experiment showed that the social behavior of rats in the high-dose long-term PCP group were reduced respective on the 3rd, 7th, 14th, 21st and 28th day after withdrawal [(16.8±4.3), (13.4±3.5), (15.5±3.9), (28.2±5.0), (32.5±4.9) s,P < 0.01], which continued on the 28th day after withdrawal. 2 The second experiment showed that the social behavior deficit of mice induced by continuous administration of high-dose PCP was obviously ameliorated at 7 days after continuous treatment with clozapine [before administration: (13.8±1.6) s, the day of drug withdrawal: (143.1±36.1) s, 7 days after withdrawal: (64.8±10.3) s, P < 0.01,P < 0.05]. There was no changes in the social behavior deficit of mice induced by low-dose of clozapine and PCP at 7 days after that. The effect of clozapine on social behavior of mice induced by PCP was attenuated at one week after withdrawal. There was no ameliorating effect of aloperidin on the social behavior of mice induced by PCP. Conclusion: The social behavior of mice can be reduced by long-term administration of PCP (10 mg/kg), while the clozapine (10 mg/kg·day) has anti-effect on that mentioned above, which indicate that long-term administration of PCP, which can change the social behavior of mice, can be taken as the antipsychotics in the treatment of social behavior animal model of schizophrenia.

The potential of the P2X7 receptor as a therapeutic target in a sub-chronic PCP-induced rodent model of schizophrenia

Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus

Changes in Gene Expression after Phencyclidine Administration in Developing Rats: a Potential Animal Model for Schizophrenia

Long-term adaptation of prefrontal circuits in a mouse model of NMDAR hypofunction

P2X7 Receptor Inhibition Prevents Atrial Fibrillation in Rodent Models of Depression.

P2X7 receptor-mediated depression-like reactions arising in the mouse medial prefrontal cortex

Impaired Limbic Cortico-Striatal Structure and Sustained Visual Attention in a Rodent Model of Schizophrenia.

Global quantitative analysis of phosphorylation underlying phencyclidine signaling and sensorimotor gating in the prefrontal cortex

Social behavior in animal model of schizophrenia and the effects of antipsychotics

Inhibition of fatty acid amide hydrolase reverses aberrant prefrontal gamma oscillations in the sub-chronic PCP model for schizophrenia

Behavioral and neurobiological changes in a novel mouse model of schizophrenia induced by the combination of cuprizone and MK-801

Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action

Acute and subchronic PCP attenuate D2 autoreceptor signaling in substantia nigra dopamine neurons

P2X7 receptors modulate acquisition of cue fear extinction and contextual background memory generalization in male mice

Inhibition of P2X7 Receptor Ameliorates Transient Global Cerebral Ischemia/reperfusion Injury Via Modulating Inflammatory Responses in the Rat Hippocampus

Targeting α6GABAA receptors as a novel therapy for schizophrenia: A proof-of-concept preclinical study using various animal models

Pharmacological Properties and Evaluations of a Novel Positive Allosteric Modulator of Α7 Nachr for Attenuation of Schizophrenia-Like Behavior in Mice

P2X7 receptor inhibition alleviates mania-like behaviour independently of IL-1β

α7 Nicotinic Acetylcholine Receptor May Be a Pharmacological Target for Perioperative Neurocognitive Disorders

Prefrontal inhibition of neuronal K<sub>v</sub>7 channels enhances prepulse inhibition of acoustic startle reflex and resistance to hypofrontality